Solid Biosciences to Participate at Upcoming Investor Conferences
- 25th Annual
Needham Virtual Healthcare Conference Bo Cumbo , President and CEO, will participate in a virtual fireside chat onTuesday, April 14, 2026 , at2:15 pm ET .
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page.
- Piper Sandler Spring Biopharma Symposium
Management will participate in one-on-one meetings onThursday, April 16, 2026 .
Institutional investors interested in meeting with management during the conference may reach out to their Needham or Piper Sandler representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases.
Solid Biosciences Investor Contact:
Senior Director, Investor Relations and Corporate Communications
investors@solidbio.com
Source: Solid Biosciences Inc.